MX385512B - Derivados de piridin-2(1h)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante. - Google Patents
Derivados de piridin-2(1h)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante.Info
- Publication number
- MX385512B MX385512B MX2019013203A MX2019013203A MX385512B MX 385512 B MX385512 B MX 385512B MX 2019013203 A MX2019013203 A MX 2019013203A MX 2019013203 A MX2019013203 A MX 2019013203A MX 385512 B MX385512 B MX 385512B
- Authority
- MX
- Mexico
- Prior art keywords
- pyridin
- isocitrate dehydrogenase
- dehydrogenase inhibitors
- mutant isocitrate
- quinolinone derivatives
- Prior art date
Links
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 title abstract 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- ASHZGMCLOXNDFT-UHFFFAOYSA-N 1H-pyridin-2-one 1H-quinolin-2-one Chemical class O=C1C=CC=CN1.C1=CC=C2NC(=O)C=CC2=C1 ASHZGMCLOXNDFT-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000003538 neomorphic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053006P | 2014-09-19 | 2014-09-19 | |
| US201562128089P | 2015-03-04 | 2015-03-04 | |
| US201562150812P | 2015-04-21 | 2015-04-21 | |
| PCT/US2015/051055 WO2016044789A1 (en) | 2014-09-19 | 2015-09-18 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019013203A MX2019013203A (es) | 2020-01-20 |
| MX385512B true MX385512B (es) | 2025-03-18 |
Family
ID=54291606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013203A MX385512B (es) | 2014-09-19 | 2015-09-18 | Derivados de piridin-2(1h)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante. |
| MX2017003404A MX2017003404A (es) | 2014-09-19 | 2015-09-18 | Derivados de piridin-2(1h)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003404A MX2017003404A (es) | 2014-09-19 | 2015-09-18 | Derivados de piridin-2(1h)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante. |
Country Status (37)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2755394C (en) | 2009-03-13 | 2021-10-19 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011050210A1 (en) * | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| RS65894B1 (sr) | 2014-02-06 | 2024-09-30 | Nxera Pharma Uk Ltd | Biciklična aza jedinjenja kao agonisti muskarinskog receptora |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| EP3201185B1 (en) | 2014-09-19 | 2018-11-21 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| SI3447050T1 (sl) | 2014-09-19 | 2020-08-31 | Forma Therapeutics, Inc. | Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze |
| EA032401B1 (ru) | 2014-09-19 | 2019-05-31 | Байер Фарма Акциенгезельшафт | Бензилзамещенные индазолы в качестве ингибиторов bub1 |
| EP3237385B1 (en) * | 2014-12-22 | 2021-11-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Mutant idh1 inhibitors useful for treating cancer |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| HUE059057T2 (hu) | 2017-05-04 | 2022-10-28 | Bayer Cropscience Ag | 2-{[2-(feniloximetil)piridin-5-il]oxi}-etánamin-származékok és rokon vegyületek mint peszticidek, például növényvédelemre |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013734B2 (en) * | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US20210196701A1 (en) * | 2018-05-16 | 2021-07-01 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| LT3720442T (lt) | 2018-05-16 | 2023-04-25 | Forma Therapeutics, Inc. | Mutantinės idh-1 slopinimas |
| WO2020232381A1 (en) | 2019-05-16 | 2020-11-19 | Forma Therapeutics, Inc. | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| TW202104207A (zh) * | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| US11566013B1 (en) * | 2019-11-20 | 2023-01-31 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1) |
| CN112341389B (zh) * | 2020-10-27 | 2022-07-29 | 浙江工业大学 | 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用 |
| CN112321571B (zh) * | 2020-10-27 | 2022-06-03 | 浙江工业大学 | 2-呋喃-喹啉-4-甲酰胺类化合物及其应用 |
| CN115850240B (zh) * | 2022-12-28 | 2023-09-19 | 北京康立生医药技术开发有限公司 | 一种治疗急性髓系白血病药物奥卢他西尼的合成方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US20030105124A1 (en) | 2000-04-27 | 2003-06-05 | Susan Beth Sobolov-Jaynes | Substituted benzolactam compounds |
| WO2003106452A2 (en) | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
| JPWO2004043936A1 (ja) | 2002-11-14 | 2006-03-09 | 協和醗酵工業株式会社 | Ｐｌｋ阻害剤 |
| RU2284325C2 (ru) * | 2003-12-17 | 2006-09-27 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе |
| EP1749827A4 (en) | 2004-03-30 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | ANTITUMOR AGENTS |
| WO2006054912A1 (fr) * | 2004-11-18 | 2006-05-26 | Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' | Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base |
| TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| WO2008010964A1 (en) * | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| JP2010043004A (ja) | 2006-12-06 | 2010-02-25 | Dainippon Sumitomo Pharma Co Ltd | 新規２環性複素環化合物 |
| CN101679321B (zh) | 2007-04-30 | 2012-10-03 | 普罗米蒂克生物科学公司 | 三嗪衍生物、含所述衍生物的组合物以及所述衍生物在制备用于治疗癌症和自身免疫性疾病药物中的应用 |
| JP2012529511A (ja) | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
| EP2509600B1 (en) * | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2012006104A2 (en) | 2010-06-28 | 2012-01-12 | Academia Sinica, Taiwan | Compounds and methods for treating tuberculosis infection |
| CN102558049B (zh) | 2010-12-17 | 2015-02-04 | 中国科学院上海药物研究所 | 一类双香豆素类化合物及其制备方法和用途 |
| US20120184548A1 (en) | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN103814020B (zh) * | 2011-06-17 | 2017-07-14 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| PH12014500682A1 (en) | 2011-09-27 | 2014-05-12 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| CA2859985C (en) | 2011-12-21 | 2020-11-03 | The Regents Of The University Of Colorado | Anti-cancer compounds targeting ral gtpases and methods of using the same |
| HUE038403T2 (hu) | 2012-01-06 | 2018-10-29 | Agios Pharmaceuticals Inc | Terápiásan alkalmazható vegyületek és alkalmazási módszereik |
| MX2015012822A (es) * | 2013-03-14 | 2016-05-31 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| CN106573897B (zh) | 2014-02-11 | 2019-09-24 | 拜耳制药股份公司 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| EP3201185B1 (en) | 2014-09-19 | 2018-11-21 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| SI3447050T1 (sl) | 2014-09-19 | 2020-08-31 | Forma Therapeutics, Inc. | Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze |
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| EP3237385B1 (en) | 2014-12-22 | 2021-11-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Mutant idh1 inhibitors useful for treating cancer |
| GB2533925A (en) | 2014-12-31 | 2016-07-13 | Univ Bath | Antimicrobial compounds, compositions and methods |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| WO2017019429A1 (en) | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| JP6930991B2 (ja) | 2016-02-26 | 2021-09-01 | セルジーン コーポレイション | 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤 |
| JP6682043B2 (ja) | 2016-06-06 | 2020-04-15 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１阻害剤 |
| WO2017223202A1 (en) | 2016-06-22 | 2017-12-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer |
| CR20190252A (es) | 2016-12-16 | 2019-08-26 | Lilly Co Eli | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes |
-
2015
- 2015-09-18 SI SI201531117T patent/SI3447050T1/sl unknown
- 2015-09-18 AU AU2015317329A patent/AU2015317329B2/en active Active
- 2015-09-18 IL IL292608A patent/IL292608B2/en unknown
- 2015-09-18 MX MX2019013203A patent/MX385512B/es unknown
- 2015-09-18 PL PL20157755.8T patent/PL3733662T3/pl unknown
- 2015-09-18 US US14/858,167 patent/US9834539B2/en active Active
- 2015-09-18 EP EP23176702.1A patent/EP4257131A3/en active Pending
- 2015-09-18 HU HUE20157755A patent/HUE062424T2/hu unknown
- 2015-09-18 SM SM20200212T patent/SMT202000212T1/it unknown
- 2015-09-18 CN CN201580050441.5A patent/CN107001328B/zh active Active
- 2015-09-18 PT PT15778433T patent/PT3194376T/pt unknown
- 2015-09-18 HU HUE15778433A patent/HUE041460T2/hu unknown
- 2015-09-18 PL PL18198969T patent/PL3447050T3/pl unknown
- 2015-09-18 SM SM20190018T patent/SMT201900018T1/it unknown
- 2015-09-18 EP EP15778433.1A patent/EP3194376B1/en active Active
- 2015-09-18 DK DK18198969.0T patent/DK3447050T3/da active
- 2015-09-18 PT PT201577558T patent/PT3733662T/pt unknown
- 2015-09-18 WO PCT/US2015/051055 patent/WO2016044789A1/en not_active Ceased
- 2015-09-18 CA CA2961817A patent/CA2961817C/en active Active
- 2015-09-18 CN CN202311265288.0A patent/CN117695280A/zh active Pending
- 2015-09-18 MY MYPI2020001463A patent/MY197533A/en unknown
- 2015-09-18 EP EP20157755.8A patent/EP3733662B1/en active Active
- 2015-09-18 DK DK15778433.1T patent/DK3194376T3/en active
- 2015-09-18 SG SG11201702194SA patent/SG11201702194SA/en unknown
- 2015-09-18 ES ES15778433T patent/ES2704897T3/es active Active
- 2015-09-18 ES ES18198969T patent/ES2790640T3/es active Active
- 2015-09-18 LT LTEP15778433.1T patent/LT3194376T/lt unknown
- 2015-09-18 EP EP18198969.0A patent/EP3447050B1/en active Active
- 2015-09-18 BR BR112017005238-5A patent/BR112017005238B1/pt active IP Right Grant
- 2015-09-18 CN CN202010391529.6A patent/CN111909130B/zh active Active
- 2015-09-18 LT LTEP18198969.0T patent/LT3447050T/lt unknown
- 2015-09-18 PE PE2017000471A patent/PE20171056A1/es unknown
- 2015-09-18 MX MX2017003404A patent/MX2017003404A/es active IP Right Grant
- 2015-09-18 TW TW104131044A patent/TWI686390B/zh active
- 2015-09-18 PT PT181989690T patent/PT3447050T/pt unknown
- 2015-09-18 KR KR1020177010585A patent/KR102209667B1/ko active Active
- 2015-09-18 JP JP2017515059A patent/JP6648115B2/ja active Active
- 2015-09-18 MA MA040481A patent/MA40481A/fr unknown
- 2015-09-18 PL PL15778433T patent/PL3194376T3/pl unknown
- 2015-09-18 ME MEP-2020-78A patent/ME03776B/me unknown
- 2015-09-18 EA EA201790657A patent/EA034336B1/ru unknown
- 2015-09-18 RS RS20200418A patent/RS60140B1/sr unknown
- 2015-09-18 FI FIEP20157755.8T patent/FI3733662T3/fi active
- 2015-09-18 ES ES20157755T patent/ES2953347T3/es active Active
- 2015-09-18 PH PH1/2017/500517A patent/PH12017500517B1/en unknown
- 2015-09-18 SI SI201530537T patent/SI3194376T1/sl unknown
- 2015-09-18 MA MA053352A patent/MA53352A/fr unknown
- 2015-09-18 RS RS20181586A patent/RS58184B1/sr unknown
- 2015-09-18 MY MYPI2017700895A patent/MY176250A/en unknown
- 2015-09-18 NZ NZ73037315A patent/NZ730373A/en unknown
-
2017
- 2017-03-07 US US15/452,256 patent/US20170174658A1/en not_active Abandoned
- 2017-03-14 IL IL251163A patent/IL251163B/en active IP Right Grant
- 2017-03-17 CL CL2017000658A patent/CL2017000658A1/es unknown
- 2017-03-19 SA SA517381129A patent/SA517381129B1/ar unknown
- 2017-03-27 ZA ZA2017/02127A patent/ZA201702127B/en unknown
- 2017-04-03 CO CONC2017/0003241A patent/CO2017003241A2/es unknown
- 2017-04-13 EC ECIEPI201722933A patent/ECSP17022933A/es unknown
-
2018
- 2018-04-27 US US15/964,844 patent/US10414752B2/en active Active
-
2019
- 2019-01-21 CY CY20191100075T patent/CY1121149T1/el unknown
- 2019-03-01 US US16/290,240 patent/US10550098B2/en active Active
- 2019-04-17 ZA ZA2019/02446A patent/ZA201902446B/en unknown
- 2019-12-12 US US16/712,951 patent/US10889567B2/en active Active
- 2019-12-16 AU AU2019283765A patent/AU2019283765B2/en active Active
-
2020
- 2020-04-24 HR HRP20200666TT patent/HRP20200666T1/hr unknown
- 2020-05-04 CY CY20201100407T patent/CY1122865T1/el unknown
- 2020-11-23 US US17/101,018 patent/US11498913B2/en active Active
-
2021
- 2021-04-18 IL IL282363A patent/IL282363B/en unknown
- 2021-08-10 AU AU2021215141A patent/AU2021215141B2/en active Active
-
2022
- 2022-11-09 US US17/984,069 patent/US20230125739A1/en not_active Abandoned
-
2023
- 2023-04-14 ZA ZA2023/04409A patent/ZA202304409B/en unknown
- 2023-11-09 US US18/506,060 patent/US12275715B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202304409B (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| MX373789B (es) | Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). | |
| MX2017003637A (es) | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). | |
| MX372986B (es) | Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) | |
| ECSP16083602A (es) | Derivados de quinolina como inhibidores smo | |
| IL263163B (en) | Substituted pyridines as inhibitors of dnmt1 | |
| TR201808169T3 (tr) | Rekombinant probiyotik bakteriler . | |
| LT3169328T (lt) | Chinolino dariniai, skirti uždegiminių ligų gydymui | |
| JO3722B1 (ar) | مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات | |
| EP3528850A4 (en) | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | |
| BR112018006157A2 (pt) | derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1 | |
| EA201791945A1 (ru) | Пирролидинкарбоксамидопроизводные и способы их получения и их применение | |
| UY34843A (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
| HRP20182176T1 (hr) | Derivati piridin-2(1h)-on kinolinona kao inhibitori mutirane izocitrat dehidrogenaze | |
| HK1242300A1 (en) | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| EA201501176A1 (ru) | Замещенные бензоксазолы | |
| EA201992489A3 (ru) | Хинолиноновые производные пиридин-2(1h)-она как ингибиторы мутантной изоцитратдегидрогеназы |